Cargando…

Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study

Neovascular age-related macular degeneration (nAMD) leads to visual impairment if not treated promptly. Intravitreal anti-VEGF drugs have revolutionized nAMD treatment in the past two decades. We evaluated the visual outcomes of anti-VEGF treatment in nAMD. A real-life population-based cohort study....

Descripción completa

Detalles Bibliográficos
Autores principales: Korva-Gurung, Ida, Kubin, Anna-Maria, Ohtonen, Pasi, Hautala, Nina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384898/
https://www.ncbi.nlm.nih.gov/pubmed/37513839
http://dx.doi.org/10.3390/ph16070927
_version_ 1785081270631399424
author Korva-Gurung, Ida
Kubin, Anna-Maria
Ohtonen, Pasi
Hautala, Nina
author_facet Korva-Gurung, Ida
Kubin, Anna-Maria
Ohtonen, Pasi
Hautala, Nina
author_sort Korva-Gurung, Ida
collection PubMed
description Neovascular age-related macular degeneration (nAMD) leads to visual impairment if not treated promptly. Intravitreal anti-VEGF drugs have revolutionized nAMD treatment in the past two decades. We evaluated the visual outcomes of anti-VEGF treatment in nAMD. A real-life population-based cohort study. The data included parameters for age, sex, age at diagnosis, laterality, chronicity, symptoms, visual outcomes, lens status, and history of intravitreal injections. A total of 1088 eyes (827 patients) with nAMD were included. Visual acuity was stable or improved in 984 eyes (90%) after an average of 36 ± 25 months of follow-up. Bevacizumab was the first-line drug in 1083 (99.5%) eyes. Vision improved ≥15 ETDRS letters in 377 (35%), >5 ETDRS letters in 309 (28%), and was stable (±5 ETDRS letters) in 298 (27%) eyes after anti-VEGF treatment. The loss of 5 ≤ 15 ETDRS letters in 44 (4%) eyes and ≥15 ETDRS letters in 60 (6%) eyes was noted. At the diagnosis of nAMD, 110 out of 827 patients (13%) fulfilled the criteria for visual impairment, whereas 179 patients (22%) were visually impaired after the follow-up. Improvement or stabilization in vision was noted in 90% of the anti-VEGF-treated eyes with nAMD. In addition, anti-VEGF agents are crucial in diminishing nAMD-related visual impairment.
format Online
Article
Text
id pubmed-10384898
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103848982023-07-30 Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study Korva-Gurung, Ida Kubin, Anna-Maria Ohtonen, Pasi Hautala, Nina Pharmaceuticals (Basel) Article Neovascular age-related macular degeneration (nAMD) leads to visual impairment if not treated promptly. Intravitreal anti-VEGF drugs have revolutionized nAMD treatment in the past two decades. We evaluated the visual outcomes of anti-VEGF treatment in nAMD. A real-life population-based cohort study. The data included parameters for age, sex, age at diagnosis, laterality, chronicity, symptoms, visual outcomes, lens status, and history of intravitreal injections. A total of 1088 eyes (827 patients) with nAMD were included. Visual acuity was stable or improved in 984 eyes (90%) after an average of 36 ± 25 months of follow-up. Bevacizumab was the first-line drug in 1083 (99.5%) eyes. Vision improved ≥15 ETDRS letters in 377 (35%), >5 ETDRS letters in 309 (28%), and was stable (±5 ETDRS letters) in 298 (27%) eyes after anti-VEGF treatment. The loss of 5 ≤ 15 ETDRS letters in 44 (4%) eyes and ≥15 ETDRS letters in 60 (6%) eyes was noted. At the diagnosis of nAMD, 110 out of 827 patients (13%) fulfilled the criteria for visual impairment, whereas 179 patients (22%) were visually impaired after the follow-up. Improvement or stabilization in vision was noted in 90% of the anti-VEGF-treated eyes with nAMD. In addition, anti-VEGF agents are crucial in diminishing nAMD-related visual impairment. MDPI 2023-06-26 /pmc/articles/PMC10384898/ /pubmed/37513839 http://dx.doi.org/10.3390/ph16070927 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Korva-Gurung, Ida
Kubin, Anna-Maria
Ohtonen, Pasi
Hautala, Nina
Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study
title Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study
title_full Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study
title_fullStr Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study
title_full_unstemmed Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study
title_short Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study
title_sort visual outcomes of anti-vegf treatment on neovascular age-related macular degeneration: a real-world population-based cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384898/
https://www.ncbi.nlm.nih.gov/pubmed/37513839
http://dx.doi.org/10.3390/ph16070927
work_keys_str_mv AT korvagurungida visualoutcomesofantivegftreatmentonneovascularagerelatedmaculardegenerationarealworldpopulationbasedcohortstudy
AT kubinannamaria visualoutcomesofantivegftreatmentonneovascularagerelatedmaculardegenerationarealworldpopulationbasedcohortstudy
AT ohtonenpasi visualoutcomesofantivegftreatmentonneovascularagerelatedmaculardegenerationarealworldpopulationbasedcohortstudy
AT hautalanina visualoutcomesofantivegftreatmentonneovascularagerelatedmaculardegenerationarealworldpopulationbasedcohortstudy